Introduction Aripiprazole is a third generation antipsychotic approved by the US Food and
Drug Administration (FDA) for the treatment of schizophrenia. Aripiprazole is available as …

Highlights•Drugs for schizophrenia are often based on dopamine blockade and have
serious side-effects.•Xanomeline/trospium may well herald the first non-dopamine based …

Background Impaired insight poses a challenge in the treatment of patients with
schizophrenia because of its potential to jeopardize therapeutic engagement and …

Introduction Poor insight, or unawareness of morbid changes in cognition, emotional states,
or behavior, is commonly observed among people with schizophrenia. Poor insight …

Objective: To conduct a targeted literature review to examine the impact of cognitive
impairment and negative symptoms among patients with schizophrenia treated in the United …

Background Antipsychotic treatment may improve clinical insight. However, previous studies
have reported inconclusive findings on whether antipsychotics improve insight over and …

Schizophrenia is a severe mental illness causing a high degree of disability. First-and
second-generation antipsychotics (FGAs and SGAs) represent key resources for its acute …

Objective: There remains a lack of clarity as to the possible cross talk of insight into illness
and depressive symptoms in treatment-resistant schizophrenia. We therefore set our primary …

Existing guidelines recommend psychopharmacological treatment for the management of
schizophrenia and bipolar disorder as part of holistic treatment concepts. About half of the …

Schizophrenia is a chronic psychiatric disorder that may lead to epilepsy. However, there
are limited findings on the issues. This narrative review aimed to provide a practical …